I. Voutsadakis

I. Voutsadakis, A. Digklia, E. Tzika, 2014, Journal of oncology pharmacy practice : official publication of the International Society of Oncology Pharmacy Practitioners.

Breast sarcomas: current and future perspectives.

K. Zaman, S. Leyvraz, I. Voutsadakis, 2011, Breast.

AFP-producing hepatoid adenocarcinoma of the stomach: a case report

P. Vlachostergios, I. Voutsadakis, C. Papandreou, 2009, Cases journal.

Epithelial to mesenchymal transition in the pathogenesis of uterine malignant mixed Müllerian tumours: the role of ubiquitin proteasome system and therapeutic opportunities

I. Voutsadakis, 2012, Clinical and Translational Oncology.

The chemosensitivity of testicular germ cell tumors

I. Voutsadakis, 2014, Cellular Oncology.

Neurotrophic receptor tyrosine kinase family members in secretory and non-secretory breast carcinomas

I. Voutsadakis, A. Stravodimou, 2022, World journal of clinical oncology.

The shaping of invasive glioma phenotype by the ubiquitin–proteasome system

P. Vlachostergios, I. Voutsadakis, C. Papandreou, 2013, Cell communication & adhesion.

Mechanisms of proteasome inhibitor-induced cytotoxicity in malignant glioma

P. Vlachostergios, I. Voutsadakis, C. Papandreou, 2013, Cell Biology and Toxicology.

The role of ubiquitin-proteasome system in glioma survival and growth

P. Vlachostergios, I. Voutsadakis, C. Papandreou, 2013, Growth factors.

Peroxisome Proliferator Activated Receptor-γ (PPARγ): Roles in Chronic Inflammation and Intestinal Oncogenic Transformation

I. Voutsadakis, 2012 .

High Mutation Burden in ER-Positive/HER2-Negative/Luminal Breast Cancers

I. Voutsadakis, 2022, Journal of clinical medicine.

Urothelial Bladder Carcinomas with High Tumor Mutation Burden Have a Better Prognosis and Targetable Molecular Defects beyond Immunotherapies

I. Voutsadakis, 2022, Current oncology.

Further Understanding of High-Grade Serous Ovarian Carcinogenesis: Potential Therapeutic Targets

I. Voutsadakis, 2020, Cancer management and research.

Clinical Implications of Chromosomal Instability (CIN) and Kinetochore Abnormalities in Breast Cancers

I. Voutsadakis, 2019, Molecular Diagnosis & Therapy.

Peroxisome proliferator-activated receptor γ (PPARγ) and colorectal carcinogenesis

I. Voutsadakis, 2007, Journal of Cancer Research and Clinical Oncology.

The Future of ER+/HER2− Metastatic Breast Cancer Therapy: Beyond PI3K Inhibitors

I. Voutsadakis, A. Stravodimou, 2020, AntiCancer Research.

High Tumor Mutation Burden and Other Immunotherapy Response Predictors in Breast Cancers: Associations and Therapeutic Opportunities

I. Voutsadakis, 2019, Targeted Oncology.

Pluripotency transcription factors in the pathogenesis of colorectal cancer and implications for prognosis.

I. Voutsadakis, 2015, Biomarkers in medicine.

Pathogenesis of colorectal carcinoma and therapeutic implications: the roles of the ubiquitin–proteasome system and Cox-2

I. Voutsadakis, 2007, Journal of cellular and molecular medicine.

A critical review of the molecular pathophysiology of lenalidomide sensitivity in 5q − myelodysplastic syndromes

I. Voutsadakis, A. Cairoli, 2012, Leukemia & lymphoma.

The pluripotency network in colorectal cancer pathogenesis and prognosis: an update.

I. Voutsadakis, 2018, Biomarkers in medicine.

The network of pluripotency, epithelial–mesenchymal transition, and prognosis of breast cancer

I. Voutsadakis, 2015, Breast cancer.

Ubiquitination and the Ubiquitin–Proteasome System as regulators of transcription and transcription factorsin epithelial mesenchymal transition of cancer

I. Voutsadakis, 2012, Tumor Biology.

Targeted treatments for metastatic esophageal squamous cell cancer.

I. Voutsadakis, A. Digklia, A. Digklia, 2013, World journal of gastrointestinal oncology.

Apoptosis and the Pathogenesis of Lymphoma

I. Voutsadakis, 2000, Acta oncologica.

Cell Models for Chromosome 20q11.21 Amplification and Drug Sensitivities in Colorectal Cancer

I. Voutsadakis, 2021, Medicina.

3q26 Amplifications in Cervical Squamous Carcinomas

I. Voutsadakis, 2021, Current oncology.

Molecular Lesions of Insulator CTCF and Its Paralogue CTCFL (BORIS) in Cancer: An Analysis from Published Genomic Studies

I. Voutsadakis, 2018, High-throughput.

The Oncotype Dx Assay in ER-Positive, HER2-Negative Breast Cancer Patients: A Real Life Experience from a Single Cancer Center.

I. Voutsadakis, S. Thibodeau, 2019, European journal of breast health.

Pre-treatment platelet counts as a prognostic and predictive factor in stage II and III rectal adenocarcinoma

I. Voutsadakis, Morgan R. Steele, 2017, World journal of gastrointestinal oncology.

Proteasome expression and activity in cancer and cancer stem cells

I. Voutsadakis, 2017, Tumour biology : the journal of the International Society for Oncodevelopmental Biology and Medicine.

The ubiquitin–proteasome system and signal transduction pathways regulating Epithelial Mesenchymal transition of cancer

I. Voutsadakis, 2012, Journal of Biomedical Science.

Molecular predictors of gemcitabine response in pancreatic cancer.

I. Voutsadakis, 2011, World journal of gastrointestinal oncology.

The TSH/Thyroid Hormones Axis and Breast Cancer

I. Voutsadakis, 2022, Journal of clinical medicine.

The ubiquitin-proteasome system in prostate cancer and its transition to castration resistance.

I. Voutsadakis, C. Papandreou, 2012, Urologic oncology.

Breast cancer sub-types display heterogeneity in gene amplification and mRNA expression of the anti-apoptotic members of BCL2 family.

I. Voutsadakis, 2023, Gene.

Characteristics and Prognosis of 8p11.23-Amplified Squamous Lung Carcinomas

I. Voutsadakis, 2023, Journal of clinical medicine.

Molecular Alterations and Putative Therapeutic Targeting of Planar Cell Polarity Proteins in Breast Cancer

I. Voutsadakis, 2023, Journal of clinical medicine.

The Landscape of PIK3CA Mutations in Colorectal Cancer.

I. Voutsadakis, 2021, Clinical colorectal cancer.

PI3KCA Mutations in Uterine Cervix Carcinoma

I. Voutsadakis, 2021, Journal of clinical medicine.

The Landscape of Chromosome Instability in Breast Cancers and Associations with the Tumor Mutation Burden: An Analysis of Data from TCGA

I. Voutsadakis, 2020, Cancer investigation.

8p11.23 Amplification in Breast Cancer: Molecular Characteristics, Prognosis and Targeted Therapy

I. Voutsadakis, 2020, Journal of clinical medicine.

Chromosome 17 centromere amplification and chromosomal instability (CIN) in breast cancer: Pathogenic and therapeutic implications.

I. Voutsadakis, 2019, Neoplasma.

Diabetes, Obesity, and the Metabolic Syndrome as Prognostic Factors in Stages I to III Colorectal Cancer Patients

I. Voutsadakis, M. Reed, C. Patrick, 2019, Journal of Gastrointestinal Cancer.

Expression and function of immune ligand-receptor pairs in NK cells and cancer stem cells: therapeutic implications

I. Voutsadakis, 2018, Cellular Oncology.

Homologous Recombination Defects and Mutations in DNA Damage Response (DDR) Genes Besides BRCA1 and BRCA2 as Breast Cancer Biomarkers for PARP Inhibitors and Other DDR Targeting Therapies

I. Voutsadakis, A. Stravodimou, 2023, AntiCancer Research.

Landscape of BRIP1 molecular lesions in gastrointestinal cancers from published genomic studies

I. Voutsadakis, 2020, World journal of gastroenterology.

Malignant female adnexal tumor of probable wolffian origin relapsing after pregnancy.

R. Rouzier, D. Atallah, P. Morice, 2004, Gynecologic oncology.

Mutations of p53 associated with pancreatic cancer and therapeutic implications

I. Voutsadakis, 2021, Annals of hepato-biliary-pancreatic surgery.

Hormone Receptors in Serous Ovarian Carcinoma: Prognosis, Pathogenesis, and Treatment Considerations

I. Voutsadakis, Ioannis A. Voutsadakis, 2016, Clinical Medicine Insights. Oncology.

Proteasome regulators in pancreatic cancer

I. Voutsadakis, N. Murugan, 2022, World journal of gastrointestinal oncology.

A systematic review and meta-analysis of hormone receptor expression in low-grade serous ovarian carcinoma.

I. Voutsadakis, 2020, European journal of obstetrics, gynecology, and reproductive biology.

Low-grade serous ovarian carcinoma: an evolution toward targeted therapy

I. Voutsadakis, 2019, International Journal of Gynecological Cancer.

Vitamin D baseline levels at diagnosis of breast cancer: A systematic review and meta-analysis.

I. Voutsadakis, 2020, Hematology/oncology and stem cell therapy.

Amplification of Chromosome 17 Centromere (CEP17) in Breast Cancer Patients with a Result of HER2 2± by Immunohistochemistry

I. Voutsadakis, V. Davies, 2020, Cancer investigation.

Immune Blockade Inhibition in Breast Cancer.

I. Voutsadakis, 2016, Anticancer research.

Prediction of Oncotype Dx recurrence score using clinical parameters: A comparison of available tools and a simple predictor based on grade and progesterone receptor.

I. Voutsadakis, S. Thibodeau, 2019, Hematology/oncology and stem cell therapy.

Bone and brain metastases from ampullary adenocarcinoma.

I. Voutsadakis, C. Papandreou, M. Papagianni, 2009, World Journal of Gastroenterology.

The ubiquitin-proteasome system in colorectal cancer.

I. Voutsadakis, 2008, Biochimica et biophysica acta.

A Systematic Review and Meta-analysis of the Combination of Vinorelbine and Lapatinib in Patients With Her2-positive Metastatic Breast Cancer

I. Voutsadakis, A. Stravodimou, 2019, AntiCancer Research.

HER2 in stemness and epithelial–mesenchymal plasticity of breast cancer

I. Voutsadakis, 2018, Clinical and Translational Oncology.

The Landscape and Therapeutic Targeting of BRCA1, BRCA2 and Other DNA Damage Response Genes in Pancreatic Cancer

I. Voutsadakis, A. Digklia, 2023, Current issues in molecular biology.

Concomitant Thymic Carcinoma With Cervical and Supraclavicular Node Metastases and Thyroid Carcinoma: Report of a Case and Literature Review

I. Voutsadakis, C. Papandreou, M. Papagianni, 2012 .

Primary Noncutaneous Malignant Melanoma of the Breast

I. Voutsadakis, Mohammad Rassouli, 2016, The breast journal.

Ubiquitin- and ubiquitin-like proteins-conjugating enzymes (E2s) in breast cancer

I. Voutsadakis, 2012, Molecular Biology Reports.

Ubiquitin, ubiquitination and the ubiquitin-proteasome system in cancer

I. Voutsadakis, 2011 .

Bortezomib reverses the proliferative and antiapoptotic effect of neuropeptides on prostate cancer cells

P. Vlachostergios, D. Daliani, I. Voutsadakis, 2012, International journal of urology : official journal of the Japanese Urological Association.

Expression of Neutral Endopeptidase, Endothelin-1, and Nuclear Factor Kappa B in Prostate Cancer: Interrelations and Associations with Prostate-Specific Antigen Recurrence after Radical Prostatectomy

P. Vlachostergios, D. Daliani, E. Zintzaras, 2012, Prostate cancer.

CD10 Is Inversely Associated with Nuclear Factor-Kappa B and Predicts Biochemical Recurrence after Radical Prostatectomy

P. Vlachostergios, D. Daliani, I. Voutsadakis, 2012, Urologia Internationalis.

CD10 and Endothelin-1 are Inversely Expressed in Early Prostate Cancer and Predict Psa Failure after Radical Prostatectomy

P. Vlachostergios, D. Daliani, I. Voutsadakis, 2011 .

A systematic review and pooled analysis of retrospective series of eribulin in metastatic breast cancer

I. Voutsadakis, 2017, Anti-cancer drugs.

Synchronous tumors of the pancreas and the gallbladder: a case report with targeted NGS evaluation.

C. Sempoux, R. Duran, I. Voutsadakis, 2019, Annals of translational medicine.

Breast Cancer in HIV-Positive Women: A Report of Four Cases and Review of the Literature

I. Voutsadakis, L. Silverman, 2002, Cancer investigation.

Breast Cancer in Patients 80 Years-Old and Older.

I. Voutsadakis, C. Rosso, A. Bertolo, 2020, European journal of breast health.

Gemtuzumab Ozogamicin (CMA-676, Mylotarg) for the treatment of CD33+ acute myeloid leukemia.

I. Voutsadakis, 2002, Anti-cancer drugs.

Polymerase epsilon mutations and concomitant β2-microglobulin mutations in cancer.

I. Voutsadakis, 2018, Gene.

Combinations of vascular endothelial growth factor pathway inhibitors with metronomic chemotherapy: Rational and current status.

I. Voutsadakis, A. Digklia, 2014, World journal of experimental medicine.

The metabolic syndrome and its components as prognostic factors in metastatic colorectal cancer

I. Voutsadakis, M. Reed, C. Patrick, 2019, Indian Journal of Gastroenterology.

KRAS mutated colorectal cancers with or without PIK3CA mutations: Clinical and molecular profiles inform current and future therapeutics.

I. Voutsadakis, 2023, Critical reviews in oncology/hematology.

A Systematic Review and Meta-analysis of Retrospective Series of Regorafenib for Treatment of Metastatic Colorectal Cancer.

I. Voutsadakis, Joey A. Mercier, 2017, Anticancer research.

Immune blockade inhibitors and the radiation abscopal effect in gastrointestinal cancers

I. Voutsadakis, 2018, World journal of gastrointestinal oncology.

Orbital Metastasis of Breast Carcinoma

P. Vlachostergios, I. Voutsadakis, C. Papandreou, 2009, Breast cancer : basic and clinical research.

A Systematic Review and Meta-analysis of PD-1 and PD-L1 Inhibitors Monotherapy in Metastatic Gastric and Gastroesophageal Junction Adenocarcinoma

I. Voutsadakis, 2020, Euroasian journal of hepato-gastroenterology.

PD-1 inhibitors monotherapy in hepatocellular carcinoma: Meta-analysis and systematic review.

I. Voutsadakis, 2019, Hepatobiliary & pancreatic diseases international : HBPD INT.

Comparison of Clinical Subtypes of Breast Cancer within the Claudin-Low Molecular Cluster Reveals Distinct Phenotypes

I. Voutsadakis, 2023, Cancers.

Factors influencing psychological wellbeing of early breast cancer patients.

I. Voutsadakis, V. Murdoch, Jessica Ivison, 2020, Reports of practical oncology and radiotherapy : journal of Greatpoland Cancer Center in Poznan and Polish Society of Radiation Oncology.

Ubiquitin- and ubiquitin-like proteins-conjugating enzymes (E2s) in breast cancer

I. Voutsadakis, 2013, Molecular Biology Reports.

Hand and Foot Syndrome associated with docetaxel treatment

I. Voutsadakis, A. Stravodimou, 2012, Acta oncologica.

Pancreatic adenocarcinomas without KRAS, TP53, CDKN2A and SMAD4 mutations and CDKN2A/CDKN2B copy number alterations: a review of the genomic landscape to unveil therapeutic avenues.

I. Voutsadakis, A. Digklia, 2023, Chinese clinical oncology.

Eribulin for heavily pre-treated metastatic breast cancer patients.

I. Voutsadakis, A. Digklia, 2015, World journal of experimental medicine.

High tumor mutation burden (TMB) in microsatellite stable (MSS) colorectal cancers: Diverse molecular associations point to variable pathophysiology.

I. Voutsadakis, 2023, Cancer treatment and research communications.

A Systematic Review and Meta-Analysis of Trifluridine/Tipiracil plus Bevacizumab for the Treatment of Metastatic Colorectal Cancer: Evidence from Real-World Series

I. Voutsadakis, Ioannis A. Voutsadakis, 2023, Current oncology.